Strs Ohio Invests $8.99 Million in Natera, Inc. $NTRA

Key Points

• Strs Ohio has invested approximately $8.99 million in Natera, Inc. by acquiring 63,590 shares during the first quarter of the year.
• Several major institutional investors, including Price T Rowe Associates and UBS AM, have significantly increased their stakes in Natera, indicating strong interest in the company.
• Despite reporting earnings that missed consensus estimates, Natera showed a 32.2% year-over-year revenue increase for the quarter, with a reported revenue of $546.60 million.

Strs Ohio acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 63,590 shares of the medical research company's stock, valued at approximately $8,992,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NTRA. Price T Rowe Associates Inc. MD raised its holdings in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares in the last quarter. Nuveen LLC purchased a new position in Natera during the 1st quarter worth approximately $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock worth $177,298,000 after purchasing an additional 732,156 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after acquiring an additional 660,538 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Natera by 8,233.5% during the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock valued at $56,270,000 after acquiring an additional 393,149 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. Stephens reissued an "overweight" rating and set a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Piper Sandler reissued an "overweight" rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price for the company in a research report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company's stock. According to MarketBeat, Natera currently has an average rating of "Buy" and an average target price of $194.00.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total value of $500,310.00. Following the sale, the insider owned 130,205 shares of the company's stock, valued at $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the sale, the chief financial officer directly owned 65,430 shares in the company, valued at approximately $8,990,082. The trade was a 4.45% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,423 shares of company stock worth $8,459,656. Insiders own 5.63% of the company's stock.

Natera Stock Performance

NASDAQ:NTRA opened at $168.51 on Friday. The firm's 50-day moving average is $155.18 and its 200-day moving average is $154.13. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $183.00. The company has a market cap of $23.13 billion, a price-to-earnings ratio of -88.23 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. The business's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.